Vertex to Participate in Upcoming March Investor Conferences
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor ...
Daily1h
Dapagliflozin prevents renal injury by improving mitochondrial function and reducing oxidative stress in diabetes patients: Study
China: A recent study published in the Journal of Diabetes and its Complications highlighted dapagliflozin's (DAPA) ...
Knowridge18h
Common diabetes drug can also prevent heart and kidney diseases
The medication, known as sodium-glucose co-transporter 2 inhibitors (SGLT2is), is already used to lower blood sugar in people ...
Science Daily10h
A diabetes, heart failure, and kidney disease medication is the first of its kind to significantly reduce both heart attacks and strokes
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...
Monthly Prescribing Reference13h
Study Investigates Whether and When to Stop Metformin in Advanced CKD
Investigators compared the outcomes of patients with type 2 diabetes who continued versus stopped metformin after progressing to stage 4 chronic kidney disease.
Cochrane14h
Does treatment with GLP-1 receptor agonists prevent complications for people with chronic kidney disease and diabetes?
• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...
ophthalmologyadvisor10h
Ocular Biomarker for Anemia Severity in Diabetic Kidney Disease Detectable on OCT
Ocular biomarkers for anemia in diabetic kidney disease include disruption of the external limiting membrane and ellipsoid zone.